Biologics market spurs blue-v-blue litigation for generics and innovators
Zentiva, Insud Pharma and an originator drug company explain how large molecule market dynamics have shifted the litigation format created by small molecule products, turning other generics and innovators into litigation targets. (Read more … )
UPC: businesses apathetic to 2019 complaint listing
In-house counsel explain what they’ve done so far to prepare for the Unified Patent Court, but say they’re unlikely to increase preparations, despite the complaint holding up the system’s creation being moved to this year’s agenda. (Read more … )
Patents abandoned by companies to save and make money
Patent departments say financial constraints have compelled more businesses to abandon or sell off less valuable registrations – but they add that they are careful not to get rid of the wrong ones. (Read more … )
Sign up to receive more content like this in Patent Strategy’s weekly newsletter.